13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000200406
Total reported value
$798.7M
$798.7M
20 檔
51.3%
During the Q3 2025 filing period, Johnson & Johnson (CIK: 0000200406) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $798.7M across 20 reported positions.
In Q3 2025, Johnson & Johnson adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 1 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 32.29% | -1.98% | — | |
| 2 | NBTX | Nanobiotix SA - Adr | Stock-Other | 21.08% | -0.06% | — | |
| 3 | MGTX | MeiraGTx Holdings plc | Stock-Other | 10.85% | +2.41% | — | |
| 4 | RAPP | Rapport Therapeutics Inc | Stock-Other | 10.52% | +0.75% | -28.56% | |
| 5 | CVRX | Cvrx Inc | Stock-Other | 6.57% | -3.25% | — | |
| 6 | LEGN | Legend Biotech Corp-adr | Stock-Other | 5.27% | +0.69% | — | |
| 7 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 4.61% | +0.10% | — | |
| 8 | PRCT | Procept Biorobotics CORP | Stock-Other | 2.54% | -0.36% | — | |
| 9 | XNCR | Xencor Inc | Stock-Other | 1.74% | +0.13% | — | |
| 10 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.69% | — | — | |
| 11 | FATE | Fate Therapeutics Inc | Stock-Other | 0.84% | +0.52% | — | |
| 12 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.67% | -0.16% | — | |
| 13 | VOR | Vor Biopharma Inc. | Stock-Other | 0.52% | — | -95.00% | |
| 14 | ✓ | Rallybio CORP | Stock-Other | 0.36% | — | — | |
| 15 | LYEL | Lyell Immunopharma Inc | Stock-Other | 0.18% | — | — | |
| 16 | NNOX | Nano-X Imaging Ltd. | Stock-Other | 0.12% | -0.03% | EXIT | |
| 17 | LAB | Standard Biotools Inc | Stock-Other | 0.08% | -0.01% | — | |
| 18 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.06% | — | — | |
| 19 | ✓ | Biomx Inc | Stock-Other | 0.01% | — | — | |
| 20 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NBTX | Nanobiotix SA - Adr | +15.2% | — | Unchanged |
| 2 | RAPP | Rapport Therapeutics Inc | +3.2% | -28.56% | Trim |
| 3 | ARWR | Arrowhead Pharmaceuticals In | +0.8% | — | Unchanged |
| 4 | CTNM | Contineum Therapeutics Inc-a | +0.6% | — | Unchanged |
| 5 | VOR | Vor Biopharma Inc. | +0.3% | -95.00% | Trim |
| 6 | NMRA | Neumora Therapeutics Inc | +0.1% | — | Unchanged |
| 7 | FATE | Fate Therapeutics Inc | +0.1% | — | Unchanged |
| 8 | SENS1GBP | Senseonics Holdings Inc | 0% | — | Unchanged |
| 9 | ✓ | Biomx Inc | 0% | — | Unchanged |
| 10 | LAB | Standard Biotools Inc | 0% | — | Unchanged |
| 11 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 12 | NNOX | Nano-X Imaging Ltd. | -0.1% | — | Unchanged |
| 13 | ✓ | Rallybio CORP | -0.3% | — | Unchanged |
| 14 | XNCR | Xencor Inc | -0.6% | — | Unchanged |
| 15 | MGTX | MeiraGTx Holdings plc | -2.3% | — | Unchanged |
| 16 | PTGX | Protagonist Therapeutics Inc | -2.4% | — | Unchanged |
| 17 | LEGN | Legend Biotech Corp-adr | -2.8% | — | Unchanged |
| 18 | PRCT | Procept Biorobotics CORP | -3.6% | — | Unchanged |
| 19 | CVRX | Cvrx Inc | -8.1% | — | Unchanged |
| 20 | LYEL | Lyell Immunopharma Inc | — | NEW | New buy |
| 21 | LYEL | Lyell Immunopharma, Inc. | — | EXIT | Sold out |
According to official SEC Form 13F filings, Johnson & Johnson reported a total U.S. public equity portfolio value of $798.7M across 20 disclosed positions in Q3 2025.
During Q3 2025, Johnson & Johnson's top holdings by market value included PTGX (32.3%)、NBTX (21.1%)、MGTX (10.8%). The largest single position, PTGX, represented 32.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, NBTX, MGTX) accounted for 51.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
LYEL
市值: $891.4K
Top Position Liquidated / Trimmed
LYEL
前期市值: $442.9K
In Q3 2025, Johnson & Johnson made 4 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 2 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.